טוען...

Targeting p300/CBP in lethal prostate cancer

Resistance to androgen receptor (AR) blockade in castration resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of the AR (AR-SV). Inhibitors of transcriptional co-activators that regulate AR activity, including the paralogue histone-ace...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Discov
Main Authors: Welti, Jonathan, Sharp, Adam, Brooks, Nigel, Yuan, Wei, McNair, Christopher, Chand, Saswati N., Pal, Abhijit, Figueiredo, Ines, Riisnaes, Ruth, Gurel, Bora, Rekowski, Jan, Bogdan, Denisa, West, William, Young, Barbara, Raja, Meera, Prosser, Amy, Lane, Jordan, Thomson, Stuart, Worthington, Jenny, Onions, Stuart, Shannon, Jonathan, Paoletta, Silvia, Brown, Richard, Smyth, Don, Harbottle, Gareth W., Gil, Veronica S., Miranda, Susana, Crespo, Mateus, Ferreira, Ana, Pereira, Rita, Tunariu, Nina, Carreira, Suzanne, Neeb, Antje J., Ning, Jian, Swain, Amanda, Taddei, David, Schiewer, Matthew J., Knudsen, Karen E., Pegg, Neil, de Bono, Johann S.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2021
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102310/
https://ncbi.nlm.nih.gov/pubmed/33431496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0751
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!